GENE ONLINE|News &
Opinion
Blog

2022-08-03| Special

Korean Companies Occupying South Korea’s Diverse Biotech Landscape

by Fujie Tham
Share To

In face of the COVID-19 pandemic, South Korea’s biotech companies have risen to the challenge of supplying the world’s vaccines, and the region is on the path to becoming one of the leading biologics manufacturers. The Korean government is actively introducing policies that favor biotech developments, such as supporting businesses to invest up to 65% of their net revenue in pharmaceutical R&Ds.

Besides launching a 2.2 trillion won (approx. $1.9 billion) plan to become one of the five largest COVID-19 vaccine manufacturing bases by 2025, the country also inaugurated 7 “Regulation Free Special Zone” to attract investments and jumpstart its homegrown biopharmaceuticals industry.

Here, GeneOnline curated some innovative and rapidly growing Korean biotechnology players, categorized by the company's core business: vaccines developments and manufacturing, large molecule and small molecule drug, and cell & gene therapy.

It's free! Log in now to read

LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top